Cempra Pharmaceuticals - Company & Market Research Reports

Cempra is a clinical-stage pharmaceutical company that focuses on developing antibiotics to treat bacterial infectious diseases. Its lead product candidates include solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community acquired bacterial pneumonia; and Taksta, an antibiotic that has completed Phase II clinical trials for refractory bone and joint infections. The company was founded in 2005 and is headquartered in Chapel Hill, North Carolina.

From
From
From
From
Gonorrhea - Pipeline Review, H2 2018 - Product Thumbnail Image

Gonorrhea - Pipeline Review, H2 2018

  • Drug Pipelines
  • 53 Pages
From
Gonorrhea - Pipeline Review, H1 2018 - Product Thumbnail Image

Gonorrhea - Pipeline Review, H1 2018

  • Drug Pipelines
  • 51 Pages
From
From
From
From
From
Bacterial Pneumonia - Pipeline Insight, 2018 - Product Thumbnail Image

Bacterial Pneumonia - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
From
From
Loading Indicator
adroll